Supramolecular cancer nanotheranostics
Abstract
Supramolecular cancer nanotheranostics have shown promising potentials in early-stage diagnosis and personal therapy. Herein, we summarize the progress of supramolecular cancer nanotheranostics and provide guidance for designing new targeted supramolecular theranostic agents.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Despite significant progress of Ru complexes in the biomedical field, their applications in deep-tissue imaging and efficient cancer therapy are constrained by limitations such as visible-light excitation/emission properties and single chemotherapy/phototherapy modality.
“Despite significant progress of Ru complexes in the biomedical field, their applications in deep-tissue imaging and efficient cancer therapy are constrained by limitations such as visible-light excitation/emission properties and single chemotherapy/phototherapy modality242,243.”
From Organic small-molecule NIR-II fluorophores for tumor phototheranostics (2026) · cites this paper as [242]
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works
Aggregation-Induced Emission: Together We Shine, United We Soar!
Mei, J., Leung, N. L. C., Kwok, R. T. K., Lam, J. W. Y., & Tang, B. Z. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00263 · Cited by 8,270 · see citing works
Hong, Y., Lam, J. W. Y., & Tang, B. Z. (2011) · Chemical Society Reviews · doi:10.1039/c1cs15113d · Cited by 6,363 · see citing works
Neutrophil recruitment and function in health and inflammation
Kolaczkowska, E., & Kubes, P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3399 · Cited by 5,472 · see citing works
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282 · see citing works
Liposomal drug delivery systems: From concept to clinical applications
Allen, T. M., & Cullis, P. R. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.037 · Cited by 4,839 · see citing works
Car t cell immunotherapy for human cancer
June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018) · Science · doi:10.1126/science.aar6711 · Cited by 3,207 · see citing works
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
Bobo, D., Robinson, K. J., Islam, J., Thurecht, K. J., & Corrie, S. R. (2016) · Pharmaceutical Research · doi:10.1007/s11095-016-1958-5 · Cited by 2,586 · see citing works
Longmire, M., Choyke, P. L., & Kobayashi, H. (2008) · Nanomedicine · doi:10.2217/17435889.3.5.703 · Cited by 2,149 · see citing works
Challenges and opportunities for structural DNA nanotechnology
Pinheiro, A. V., Han, D., Shih, W. M., & Yan, H. (2011) · Nature Nanotechnology · doi:10.1038/nnano.2011.187 · Cited by 1,292 · see citing works
Tumor suppressors and cell metabolism: a recipe for cancer growth
Jones, R. G., & Thompson, C. B. (2009) · Genes & Development · doi:10.1101/gad.1756509 · Cited by 1,085 · see citing works
Perioperative events influence cancer recurrence risk after surgery
Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556 · see citing works
Liu, R., Xiao, W., Hu, C., Xie, R., & Gao, H. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.04.005 · Cited by 250 · see citing works
Sun, Y., Ding, F., Zhou, Z., Li, C., Pu, M., Xu, Y., Zhan, Y., Lu, X., Li, H., Yang, G., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817021116 · Cited by 165 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
NIR‐II Emissive Ru(II) Metallacycle Assisting Fluorescence Imaging and Cancer Therapy
Fan, Y., Li, C., Bai, S., Ma, X., Yang, J., Guan, X., & Sun, Y. (2022) · Small · doi:10.1002/smll.202201625 · Cited by 51 · see citing works
Xu, Y., Dou, Y., Li, Q., Ye, H., Li, Y., Qiu, S., Xiong, X., Li, J., & Sun, Y. (2023) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2023.215320 · Cited by 39 · see citing works
Beygi, M., Oroojalian, F., Hosseini, S. S., Mokhtarzadeh, A., Kesharwani, P., & Sahebkar, A. (2023) · Progress in Materials Science · doi:10.1016/j.pmatsci.2023.101209 · Cited by 32 · see citing works
RetractedZhang, Z., Ye, H., Cai, F., & Sun, Y. (2023) · Dalton Transactions · doi:10.1039/d3dt01893h · Cited by 17 · see citing works
Organic small-molecule NIR-II fluorophores for tumor phototheranostics
Xiang, D., Wang, Z., Zheng, H., Tang, Y., & Li, Q. (2026) · Light: Science & Applications · doi:10.1038/s41377-026-02212-w · Cited by 22 · see citing works
“Despite signi fi cant progress of Ru complexes in the biomedical fi eld, their applications in deep-tissue imaging and ef fi cient cancer therapy are constrained by limitations such as visible-light excitation/emission properties and single chemotherapy/phototherapy modality 242,243 .”
- Authors
- Zhou, J., Rao, L., Yu, G., Cook, T. R., Chen, X., & Huang, F.
- Affiliations
- State Key Laboratory of Chemical Engineering (CN)
- National Institutes of Health (US)
- State University of New York (US)
- National University of Singapore (SG)
- Zhengzhou University (CN)
- Corresponding author
- Yu, Guocan
- Cook, Timothy R.
- Chen, Xiaoyuan
- Huang, Feihe
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2021
- Volume
- 50
- Issue
- 4
- Pages
- 2839-2891
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W3128962903
- Cited by
- 411
- References
- 15
- Citations by year
- 2026: 18 · 2025: 61 · 2024: 81 · 2023: 103 · 2022: 104 · 2021: 44
- FWCI
- 7.02
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Society Reviews (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (22035006)
- Natural Science Foundation of Zhejiang Province (LD21B020001)
- Fundamental Research Funds for the Central Universities
- Topics
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Advanced biosensing and bioanalysis techniques
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Keywords
- cancer nanomedicine, theranostic agents, cancer diagnosis, cancer therapy, targeted drug delivery, early-stage cancer detection, personalized medicine, supramolecular chemistry
- MeSH terms
- Theranostic Nanomedicine, Animals, Antineoplastic Agents, Biological Transport, DNA, Humans, Liposomes, Neoplasms, Nucleotides, Organometallic Compounds, Proteins, Nanostructures, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
